Abstract
Anxiety disorders and alcohol use disorders are common psychiatric illnesses. Comorbidity of the two disorders can have a tremendous effect on treatment of one or both disorders, as well as an individual’s social, economic, and physical well-being. We estimated genome-wide genetic correlations between anxiety and alcohol use traits using linkage disequilibrium score regression (LDSC) and found strong and positive correlations of anxiety with problematic alcohol use (PAU), but not with most alcohol consumption (AC) measures. We observed strong, positive between-sex genetic correlations for all traits, but found suggestive evidence that the genetic correlation between alcohol use and anxiety might differ between males and females. Estimates of local genetic covariance demonstrated divergent genetic covariance profiles of PAU and AC with anxiety phenotypes and localized 12 specific genomic regions that likely contribute to both anxiety and alcohol use. Finally, partitioning the genetic covariance among functional annotations also identified the amygdala, caudate basal ganglia and frontal cortex as contributing significantly to positive genetic covariance between anxiety and PAU phenotypes. This study serves as a framework for an approach to be used in future analyses of the genetics of comorbid disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been conducted using the UK Biobank Resource under application number 1665. This work was supported by NIH MH100141 (PI: M.C. Keller), AG046938 (PI: C.A. Reynolds/S.M. Wadsworth), 5T32MH016880- 38 (PI: John Hewitt), F32AA027435 (PI: E.C. Johnson), R01 NS086933 (PI: C.A. Hoeffer), T32MH016880 (PI: C.A. Hoeffer), the Linda Crnic Institute, Le Jeune Foundation and Institute for Behavioral Genetics. This work utilized the Summit supercomputer, which is supported by the National Science Foundation (awards ACI-1532235 and ACI-1532236), the University of Colorado Boulder, and Colorado State University. The Summit supercomputer is a joint effort of the University of Colorado Boulder and Colorado State University. This work was conducted using the summary statistics from the Psychiatric Genomics Consortium's Substance Use Disorders Working group. The Psychiatric Genomics Consortium's Substance Use Disorders (PGC-SUD) working group is supported by MH109532 with funding from NIMH and NIDA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB and/or ethics committee approvals were necessary.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary statistics used in this study were publicly available and access links can be found in original publications.
